Skip to content
About
Leadership
Executive Team
Board of Directors
Facilities
Therapeutic Areas Overview
Central Nervous System
Fibromyalgia
Migraine
Immunology
Organ Transplant Rejection
Gastro-Intestinal Cancers
Infectious Disease
Lyme Disease
Mpox (Monkey Pox)
Smallpox
Rare Disease
Prader-Willi Syndrome
Pipeline
Central Nervous System
TNX-102 SL
Immunology
TNX-1500
TNX-1700
Infectious Disease
TNX-4800
TNX-801
TNX-4200 CD45
Rare Disease
TNX-2900
Expanded Access Policy
Medicines
Clinical Trials
News & Events
Press Releases
Tonix in the News
Tonix Sponsored News
Investor Presentations
Scientific Presentations
IR Events
Op-eds
Investors
News & Events
Presentations
Investor Presentations
Scientific Presentations
Program Specific Presentations
Conference Materials
Multimedia
Financial Info
Stock Data
SEC Filings
Governance
Careers
Contact Us
June 2024
ATC 2024: Extended Survival of 9- and 10-Gene Edited Pig Heart Xenografts with Ischemia Minimization and CD154 Costimulation Blockade –Based Immunosuppression
June 2024
ATC 2024: Delayed Immune Tolerance for Cardiac Allografts in Nonhuman Primates by Targeting CD154, CD2, and CD28 Costimulation Pathways
June 2024
ASCP Annual Meeting 2024: Effects of Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) on Mood and Anxiety Symptoms in Fibromyalgia
May 2024
ASCP Annual Meeting 2024: Fibromyalgia-Type Long COVID
May 2024
ASCP Annual Meeting 2024: Acute Stress Disorder
April 2024
AACR Annual Meeting 2024: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody
April 2024
World Vaccine Congress 2024: Attenuation of the Horsepox Virus Platform as a Vaccine for Mpox/Smallpox (TNX-801)
March 2024
American Chemistry Society (ACS) Spring 2024: Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations
March 2024
Controversies in Fibromyalgia 2024: Efficacy and Safety of TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia: Results from the Phase 3 Randomized, Double-Blind, Placebo-Controlled RESILIENT Trial
March 2024
Controversies in Fibromyalgia: Tonmya* (TNX-102 SL) in Development for the Management of Fibromyalgia
Posts navigation
Older posts
Newer posts